BBB Penetrating ADC

The reason for HER2 paradigm – improvement of systemic disease control on one hand and outbreak of brain metastases on the other, is that the central nervous system (CNS) is considered as a sanctuary site for metastatic tumor growth. In fact, many therapeutics highly effective outside of the CNS do not work well once the cancer spreads to brains. Particularly, the blood-brain barrier (BBB) stands as a major obstacle preventing drugs including mAbs and antibody-drug conjugates (ADCs) to efficiently accumulate at their pharmacological concentrations in brains. We aim to develop brain penetrating ADCs able to efficiently cross BBB and thus significantly improve treatment efficacy of brain metastases. If successful, this platform technology can be readily applied to biologics against primary brain tumor and other CNS diseases suffering from BBB blockage.